ALT - NASDAQ
Altimmune, Inc.
$2.87
-1.0%Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
At a Glance
Live SnapshotAltimmune, Inc. Management Team
Mr. Raymond M. Jordt M.B.A.
Chief Business Officer
Compensation
$578,850
Mr. Gregory L. Weaver CPA, M.B.A.
Chief Financial Officer
Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS
Chief Medical Officer
Compensation
$690,737
Dr. M. Scot Roberts Ph.D.
Chief Scientific Officer
Compensation
$648,960
Mr. Bertrand Georges Ph.D.
Chief Technology Officer
Dr. Vipin K. Garg Ph.D.
President, Chief Executive Officer & Director
Compensation
$992,999
Mr. Andrew Shutterly M.S.
Principal Financial & Accounting Officer and Corporate Controller
Mr. Tony Blandin B.S.
Vice President of Quality & Compliance Management
Altimmune, Inc. Insider Positioning
During the last 12 months, insiders have purchased $2.06M worth of ALT shares, with no selling activity reported.
3 Months
59.2K
198.44K
0
0.00
+198K
+$198K
3-6 Months
31.0K
127.35K
0
0.00
+127K
+$127K
6-9 Months
439.2K
1.72M
0
0.00
+1.7M
+$1.72M
9-12 Months
4.2K
13.29K
0
0.00
+13K
+$13K
Top Buyers
Durso Jerome Benedict
Director, Officer: President And Ceo
$361K
Gill John
Director
$274K
Pisano Wayne
Director
$212K
Sohn Catherine A.
Director
$193K
Jorkasky Diane
Director
$193K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $2.06M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
SEC Filings
ALT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | March 17, 2026 | April 16, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | August 15, 2025 | September 25, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | August 15, 2024 | September 26, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | August 16, 2023 | September 28, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | August 16, 2022 | September 29, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | August 16, 2021 | September 23, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | August 21, 2020 | September 24, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | August 22, 2019 | September 26, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | July 26, 2018 | August 30, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | September 01, 2017 | October 13, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.